Osteosarcoma (OS) is the commonest sort of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the result for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to elucidate the resistance of OS to chemotherapy is that the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis.
HTML PDFShare this article
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report
